| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000043042 |
| Receipt No. | R000049140 |
| Scientific Title | Study on the relationship between oral volatile sulfur compounds and chewy foods containing lactic acid bacteria. |
| Date of disclosure of the study information | 2021/01/19 |
| Last modified on | 2022/08/25 (Ver. 4) |
| Basic information | ||
| Public title | Study on the relationship between oral volatile sulfur compounds and chewy foods containing lactic acid bacteria. | |
| Acronym | Study on the relationship between breath odors and chewy foods containing lactic acid bacteria. | |
| Scientific Title | Study on the relationship between oral volatile sulfur compounds and chewy foods containing lactic acid bacteria. | |
| Scientific Title:Acronym | Study on the relationship between breath odors and chewy foods containing lactic acid bacteria. | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate the effect of ingestion of chewy foods containing lactic acid bacteria on the generation of volatile sulfur compounds during masking. At the same time, changes in physical condition, etc. will be confirmed in order to understand the improvement of immune-related QOL. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Amount of change in oral gas concentration. |
| Key secondary outcomes | Analysis of oral flora (e.g. correlation with volatile sulfide compounds).
Immune-related changes in quality of life. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Food containing active ingredients, 4pieces /day, 28 consecutive days. | |
| Interventions/Control_2 | Food without active ingredients, 4pieces /day, 28 consecutive days. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Subjects who gave written informed consent to participate in the study.
2) Individuals who are diagnosed as having no health problems based on a physician's interview. 3) Men and women aged 20-65 years at the time of informed consent. 4) Non-smokers for at least 1 year. 5) Persons who have not undergone dental treatment or cleaning by a dentist within 6 months retrospectively from the date of the screening examination. 6) Those who have 24 or more teeth left behind. |
|||
| Key exclusion criteria | 1) Pregnant women or women of childbearing potential, and women who wish to become pregnant during the study period.
2) Lactating women. 3) Persons with a history of serious disease (including Sjoegren's syndrome). 4) Persons with a history of hypersensitivity to gelatin or sugar alcohols. 5) Persons who may require dental treatment (including orthodontic treatment) during the study participation period. 6) Persons who has undergone extraction procedures other than tooth extraction for convenience in wisdom tooth extraction or orthodontic treatment. 7) Patients who have taken antibiotics (antibiotics/antibiotics) within 3 months. 8) Persons who may use antihistamines (due to hay fever, allergies, etc.) during the study period (use of antihistamines and cold medications will be investigated in a pre-questionnaire or diary). 9) Persons who do not show an increase in oral gas concentration after wearing a mask in the measurement of oral gas concentration during screening. 10) Other persons who the investigator or the investigator judges to be inappropriate as subjects of the study. |
|||
| Target sample size | 40 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Otsuka Pharmaceutical,Co.,Ltd. | ||||||
| Division name | Otsu Nutraceuticals Research Institute | ||||||
| Zip code | 520-0002 | ||||||
| Address | 3-31-13, Saikawa, Otsu-shi, Shiga 520-0002, Japan | ||||||
| TEL | 077-521-8835 | ||||||
| Saito.Hiroshi@otsuka.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Otsuka Pharmaceutical,Co.,Ltd. | ||||||
| Division name | Otsu Nutraceuticals Research Institute | ||||||
| Zip code | 520-0002 | ||||||
| Address | 3-31-13, Saikawa, Otsu-shi, Shiga 520-0002, Japan | ||||||
| TEL | 077-521-8835 | ||||||
| Homepage URL | |||||||
| Saito.Hiroshi@otsuka.jp | |||||||
| Sponsor | |
| Institute | Otsuka Pharmaceutical,Co.,Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Otsuka Pharmaceutical,Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Japan Conference of Clinical Research |
| Address | Ikebukuro YS Bldg. 8F, 1-13-23 Minami-ikebukuro, Toshima-ku, Tokyo 171-0022,Japan |
| Tel | 03-6868-7022 |
| ishii-keiko@3hcts.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000049140 |